Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cidara Therapeutics (CDTX) Debt to Equity: 2017-2022

Historic Debt to Equity for Cidara Therapeutics (CDTX) over the last 5 years, with Jun 2022 value amounting to -$0.02.

  • Cidara Therapeutics' Debt to Equity fell 106.55% to -$0.02 in Q2 2022 from the same period last year, while for Jun 2022 it was -$0.02, marking a year-over-year decrease of 106.55%. This contributed to the annual value of $0.12 for FY2021, which is 81.68% down from last year.
  • Per Cidara Therapeutics' latest filing, its Debt to Equity stood at -$0.02 for Q2 2022, which was up 95.01% from -$0.40 recorded in Q1 2022.
  • Over the past 5 years, Cidara Therapeutics' Debt to Equity peaked at $3.13 during Q1 2021, and registered a low of -$3.20 during Q3 2021.
  • Over the past 3 years, Cidara Therapeutics' median Debt to Equity value was $0.20 (recorded in 2020), while the average stood at $0.13.
  • The largest annual percentage gain for Cidara Therapeutics' Debt to Equity in the last 5 years was 1,586.48% (2021), contrasted with its biggest fall of 1,261.60% (2021).
  • Cidara Therapeutics' Debt to Equity (Quarterly) stood at $0.17 in 2018, then surged by 56.89% to $0.26 in 2019, then surged by 148.86% to $0.66 in 2020, then tumbled by 81.68% to $0.12 in 2021, then tumbled by 106.55% to -$0.02 in 2022.
  • Its Debt to Equity stands at -$0.02 for Q2 2022, versus -$0.40 for Q1 2022 and $0.12 for Q4 2021.